Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors

Advances in Anatomic Pathology

Volumn 20, Issue 1, 2013, Pages 32-38

  Schaap, Frank G ^a,c   French, Pim J ^b   Bovée, Judith V M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

epigenome; hypoxic signaling; IDH mutation; tumor metabolism

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; TRICARBOXYLIC ACID;

ANGIOGENESIS; CANCER GROWTH; CARTILAGE TUMOR; ENERGY METABOLISM; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GLIOMA; HUMAN; HYPOXIA; LEUKEMIA; PRIORITY JOURNAL; REVIEW;

BONE NEOPLASMS; BRAIN NEOPLASMS; CARTILAGE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA; MUTATION;

EID: 84871731169     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31827b654d     Document Type: Review

References (90)

1. Warburg O. On the origin of cancer cells. Science. 1956;123: 309-314.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
3. Bayley JP, Devilee P. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev. 2010;20:324-329.
4. Nilsson LM, Forshell TZ, Rimpi S, et al. Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis. PLoS Genet. 2012;8:e1002573.
5. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009;9:691-700.
6. Bayley JP, Devilee P. The Warburg effect in 2012. Curr Opin Oncol. 2012;24:62-67.
7. Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med. 2011;17: 641-649.
8. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321: 1807-1812.
9. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
10. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334-343.
11. Yen KE, Schenkein DP. Cancer-associated isocitrate dehydrogenase mutations. Oncologist. 2012;17:5-8.
12. Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011;43:1262-1265.
13. Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 or IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43:1256-1261.
14. Meijer D, de Jong D, Pansuriya TC, et al. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer. 2012;51: 899-909.
15. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469-474.
16. Kloosterhof NK, Bralten LB, Dubbink HJ, et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. 2011;12:83-91.
17. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058-1066.
18. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24:1094-1096.
19. Zhang Y, Wei H, Tang K, et al. Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia. Genet Test Mol Biomarkers. 2012;16:991-995.
20. Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119:1901-1903.
21. Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012; 43:1552-1558.
22. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72-79.
23. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2012; In press [published online ahead of print July 23, 2012; doi: 10. 038/onc.2012.315].
24. Shibata T, Kokubu A, Miyamoto M, et al. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol. 2011;178:1395-1402.
25. Yen KE, Bittinger MA, Su SM, et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010;29:6409-6417.
26. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125:353-355.
27. Gaal J, Burnichon N, Korpershoek E, et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2010;95: 1274-1278.
28. Hemerly JP, Bastos AU, Cerutti JM. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol. 2010;163:747-755.
29. Pietrak B, Zhao H, Qi H, et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of alphaHG. Biochemistry. 2011;50:4804-4812.
30. Bovee JVMG, Hogendoorn PCW, Wunder JS, et al. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer. 2010;10:481-488.
31. Fletcher CDM, Unni KK, Mertens F. WHO Classification of Tumours. Pathology & Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:1-427.
32. Pansuriya T, Kroon HM, Bovee JVMG. Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol. 2010;3:557-569.
33. Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008; 13:320-329. (Pubitemid 351679908)
34. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40:818-831. (Pubitemid 8177905)
35. Rozeman LB, Hameetman L, van Wezel T, et al. cDNA expression profiling of central chondrosarcomas: Ollier disease resembles solitary tumors and alteration in genes coding for energy metabolism with increasing grade. J Pathol. 2005;207:61-71. (Pubitemid 41200715)
36. Hameetman L, Rozeman LB, Lombaerts M, et al. Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog (IHH) signalling. J Pathol. 2006;209:501-511. (Pubitemid 44194565)
37. Boeuf S, Bovee JVMG, Lehner B, et al. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology. 2010;56:641-651.
38. Lin C, McGough R, Aswad B, et al. Hypoxia induces HIF- 1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res. 2004;22:1175-1181. (Pubitemid 39317905)
39. Chen C, Zhou H, Wei F, et al. Increased levels of hypoxiainducible factor-1alpha are associated with Bcl-xL expression, tumor apoptosis, and clinical outcome in chondrosarcoma. J Orthop Res. 2011;29:143-151.
40. Kalinski T, Krueger S, Sel S, et al. Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interleukin-1beta. Cancer. 2006;106:2028-2038. (Pubitemid 43673220)
41. McGough RL, Lin C, Meitner P, et al. Angiogenic cytokines in cartilage tumors. Clin Orthop Relat Res. 2002;397:62-69. (Pubitemid 34442016)
42. Kubo T, Sugita T, Shimose S, et al. Expression of hypoxiainducible factor-1alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. J Bone Joint Surg Br. 2008;90:364-370. (Pubitemid 351428956)
43. Schrage YM, Briaire-de Bruijn IH, de Miranda NFCC, et al. Kinome profiling of chondrosarcoma reveals Src-pathway activity and dasatinib as option for treatment. Cancer Res. 2009;69:6216-6222.
44. Vissers LE, Fano V, Martinelli D, et al. Whole-exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria (MC-HGA). Am J Med Genet A. 2011;155A:2609-2616.
45. Kranendijk M, Struys EA, Van SE, et al. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science. 2010;330:336.
46. .Damato S, Alorjani M, Bonar F, et al. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology. 2012;60:363-365.
47. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453. (Pubitemid 47339290)
48. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149-1153.
49. Ichimura K. Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol. 2012;29:131-139.
50. Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 2012; 149:36-47.
51. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510-522.
52. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599-612.
53. .Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17:13-27.
54. .Akalin A, Garrett-Bakelman FE, Kormaksson M, et al. Basepair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 2012;8:e1002781.
55. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474-478.
56. .Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hyp ermethylator phenotype. Nature. 2012;483:479-483.
57. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553-567.
58. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17-30.
59. Mullen AR, Wheaton WW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481:385-388.
60. Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481:380-384.
61. Bolduc JM, Dyer DH, Scott WG, et al. Mutagenesis and Laue structures of enzyme intermediates: isocitrate dehydrogenase. Science. 1995;268:1312-1318.
62. Sasaki M, Knobbe CB, Munger JC, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012;488:656-659.
63. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225-234.
64. Gross S, Cairns RA, Minden MD, et al. Cancerassociated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207:339-344.
65. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-744.
66. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4, 116ra4.
67. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18:624-629.
68. Kranendijk M, Struys EA, Salomons GS, et al. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis. 2012;35:571-587.
69. Putiri EL, Robertson KD. Epigenetic mechanisms and genome stability. Clin Epigenetics. 2011;2:299-314.
70. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011;25:1010-1022.
71. .Branco MR, Ficz G, Reik W. Uncovering the role of 5- hydroxymethylcytosine in the epigenome. Nat Rev Genet. 2012;13:7-13.
72. Yang H, Liu Y, Bai F, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2012; In press. [published online ahead of print March 5, 2012; doi: 10.1038/onc.2012.7].
73. Kudo Y, Tateishi K, Yamamoto K, et al. Loss of 5- hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012;103:670-676.
74. McDonough MA, Loenarz C, Chowdhury R, et al. Structural studies on human 2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol. 2010;20:659-672.
75. Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12:463-469.
76. Duncan CG, Barwick BG, Jin G, et al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 2012; In press. [published online ahead of print November 1, 2012; doi: 10.101/ gr.132738.111].
77. Robey IF, Lien AD, Welsh SJ, et al. Hypoxia-inducible factor- 1alpha and the glycolytic phenotype in tumors. Neoplasia. 2005;7:324-330. (Pubitemid 40664221)
78. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12:9-22.
79. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261-265.
80. Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483:484-488.
81. Sasaki M, Knobbe CB, Itsumi M, et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 2012;26: 2038-2049.
82. Reitman ZJ, Jin G, Karoly ED, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA. 2011;108:3270-3275.
83. .Eng C, Kiuru M, Fernandez MJ, et al. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer. 2003;3:193-202. (Pubitemid 37328871)
84. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848-851. (Pubitemid 30084326)
85. Douwes Dekker PB, Corver WE, Hogendoorn PC, et al. Multiparameter DNA flow-sorting demonstrates diploidy and SDHD wild-type gene retention in the sustentacular cell compartment of head and neck paragangliomas: chief cells are the only neoplastic component. J Pathol. 2004;202: 456-462. (Pubitemid 38456164)
86. Burnichon N, Vescovo L, Amar L, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20:3974-3985.
87. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406-410.
88. Liu Z, Xu J, Colvin JS, et al. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev. 2002;16:859-869. (Pubitemid 34280109)
89. Lehtonen R, Kiuru M, Vanharanta S, et al. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol. 2004;164:17-22. (Pubitemid 38364585)
90. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)